Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Copyright 2024 – Finance News Network
Source: Finance News Network
27 Jan 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt analyses December's breast cancer data, and provides an update on efti's position and outlook.e sites.
Read More07 Apr 2025 - The Final Steps in Drug Development and Market Access
Read More19 Dec 2023 - James Powell, General Manager - Investor Relations, Corporate Affairs and Sustainability for Rural Funds Management presents on the FY23 results of the Rural Funds Group (ASX:RFF).
Read More14 Oct 2024 - Hiremii Limited (ASX:HMI) Managing Director and CEO Andrew Hornby discusses revolutionising recruitment through AI integration, touching on the company's revenue growth, international expansion, and opportunities in the resources and energy sectors.
Read More2 Aug 2022 - Laybuy Holdings Limited (ASX:LBY) Co-Founder and Managing Director Gary Rohloff discusses quarterly results, restructuring of the company and outlook.
Read More24 Jan 2024 - Investment expert Winston Sammut discusses recent M&A activity in the property sector, analyzing BWP Trust's bid for Newmarket and Aspen's offer for Eureka Holdings. Sammut shares insights on deal rationale, pricing concerns, and potential market implications.
Read More06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.
Read More17 Nov 2023 - Shaw and Partners Chief Investment Office Martin Crabb discusses when to get more bullish on equities.
Read More11 Dec 2020 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director James McBrayer talks about USFDA approval for Technegas, the company's USA commercialisation plan, and opportunities beyond its key diagnostic market for pulmonary embolism.
Read More01 Apr 2022 - Lepidico Limited (ASX:LPD) Managing Director Joe Walsh discusses the progress of the company's Karibib lithium operations and Abu Dhabi processing plant, potential capital raisings and offtake agreements.
Read More
